Opinion|Videos|June 20, 2024

Real-World Evidence from the IMDC

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Toni K. Choueiri, MD

Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.

Episodes in this series

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 1 EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 2 The Role of ctDNA in Genitourinary Cancer

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 3 KIM-1: Biomarker Analysis in IMmotion010 in RCC

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 4 Real-World Evidence from the IMDC

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 5 PSMAfore: Health-Related QoL and Pain in Taxane-Naïve Patients with mCRPC

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

September 28th, 2026

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Denosumab Biosimilar Approved For Existing Oncology Indications

Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC

FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026

Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer

New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC